PMID- 30118441
OWN - NLM
STAT- MEDLINE
DCOM- 20181119
LR  - 20181119
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Print)
IS  - 1234-1010 (Linking)
VI  - 24
DP  - 2018 Aug 17
TI  - Inhibition of C-X-C Motif Chemokine 10 (CXCL10) Protects Mice from Cigarette 
      Smoke-Induced Chronic Obstructive Pulmonary Disease.
PG  - 5748-5753
LID - 10.12659/MSM.909864 [doi]
AB  - BACKGROUND Chronic obstructive pulmonary disease (COPD) is a type of obstructive 
      lung disease characterized by long-term breathing problems and poor airflow. COPD 
      can progress to persistent decline of pulmonary function. This study explored the 
      effect of CXCL10 on COPD induced by cigarette smoke (CS) and its underlying 
      mechanism. MATERIAL AND METHODS Wild-type (WT) mice were randomly assigned into 3 
      groups: the control group, the CS group, and the intervention group. Mice in the 
      CS group were exposed to CS and mice in the CXCL10 group were exposed to CS and 
      CXCL10 neutralizing antibody. At 24 h after the last CS exposure, body weight and 
      lung functions of each mouse were recorded. Mice were then anesthetized for 
      collecting bronchoalveolar lavage fluid (BALF) and lung tissues. Levels of 
      interleukin-6 (IL-6), keratinocyte chemotactic factor (KC), and monocyte 
      chemoattractant protein-1 (MCP-1) in supernatant and lung homogenate were 
      detected by ELISA and real-time PCR (RT-PCR), respectively. For in vitro 
      experiments, human bronchial epithelial cells 16HBE were stimulated with 
      different concentrations of cigarette smoke extract (CSE) and CXCL10. Cell 
      viability and levels of inflammatory cytokines in the cell supernatant were 
      detected by Cell Counting Kit-8 (CCK-8) and ELISA assay, respectively. RESULTS 
      Our data showed significant weight loss and reduction of lung functions in mice 
      in the CS group compared with those in the control group and intervention group. 
      Increased levels of IL-6, KC, and MCP-1 in BALF and lung homogenate were observed 
      in mice in the model group compared to those in the control group and 
      intervention group. In vitro experiments also confirmed that CXCL10-neutralizing 
      antibody can inhibit CSE-induced cell necrosis and activation of inflammatory 
      cytokines. CONCLUSIONS Inhibited CXCL10 protects against COPD progression by 
      decreasing secretion of inflammatory factors, which provides a new direction for 
      the clinical prevention and treatment of COPD.
FAU - Jing, Hongyu
AU  - Jing H
AD  - Department of Respiratory Medicine, First Hospital of Jilin University, 
      Changchun, Jilin, China (mainland).
FAU - Liu, Lingyun
AU  - Liu L
AD  - Department of Andrology, First Hospital of Jilin University, Changchun, Jilin, 
      China (mainland).
FAU - Zhou, Junfeng
AU  - Zhou J
AD  - Department of Dermatology and Venereology, First Hospital of Jilin University, 
      Changchun, Jilin, China (mainland).
FAU - Yao, Hanxin
AU  - Yao H
AD  - Department of Clinical Laboratory, First Hospital of Jilin University, Changchun, 
      Jilin, China (mainland).
LA  - eng
PT  - Journal Article
DEP - 20180817
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and 
      clinical research
JID - 9609063
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Chemokine CXCL10)
RN  - 0 (Inflammation Mediators)
SB  - IM
MH  - Animals
MH  - Antibodies, Neutralizing/pharmacology
MH  - Cell Line
MH  - Chemokine CXCL10/*antagonists & inhibitors/metabolism
MH  - Humans
MH  - Inflammation/metabolism/pathology
MH  - Inflammation Mediators/metabolism
MH  - Male
MH  - Mice
MH  - Pulmonary Disease, Chronic Obstructive/*etiology/physiopathology/*prevention & 
      control
MH  - Respiratory Function Tests
MH  - Smoking/*adverse effects
PMC - PMC6109363
COIS- Conflict of interest None.
EDAT- 2018/08/18 06:00
MHDA- 2018/11/20 06:00
PMCR- 2018/08/17
CRDT- 2018/08/18 06:00
PHST- 2018/08/18 06:00 [entrez]
PHST- 2018/08/18 06:00 [pubmed]
PHST- 2018/11/20 06:00 [medline]
PHST- 2018/08/17 00:00 [pmc-release]
AID - 909864 [pii]
AID - 10.12659/MSM.909864 [doi]
PST - epublish
SO  - Med Sci Monit. 2018 Aug 17;24:5748-5753. doi: 10.12659/MSM.909864.